论文部分内容阅读
在日前举行的2014年中国心脏病大会上,国家心血管病中心、阜外心血管病医院蒋立新教授指出,2001~2011年,我国急性心肌梗死住院患者人数增加4倍,但住院病死率及主要并发症发生率等并无明显下降,再灌注治疗10年间无明显改善,是制约我国急性心梗治疗疗效提升的最大短板。同时,北京协和医院副院长兼临床药理研究中心主任张抒杨表示,10年来,我国在心血管病治疗领域的治疗能力大幅提高,制定了大量指南,
At the 2014 China Heart Disease Conference held recently, Professor Jiang Lixin, director of the National Cardiovascular Center and Fu Wai Cardiovascular Hospital, pointed out that the number of hospitalized patients with acute myocardial infarction in our country increased four-fold from 2001 to 2011, but the in-hospital mortality and The incidence of major complications such as no significant decline in reperfusion therapy for 10 years without significant improvement is to restrict the efficacy of acute myocardial infarction therapy in China to enhance the largest short board. Meanwhile, Zhang Shuyang, vice president of Peking Union Medical College Hospital and director of the Center for Clinical Pharmacology and Research, said that over the past 10 years, China has made tremendous efforts in the treatment of cardiovascular diseases and has formulated a large number of guidelines.